Doravirine: all 41 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingNCT07862569Phase 2
• Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingNCT07357584Phase 4
• Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH SuccessfullyRecruitingNCT06774872Phase 2
• Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTIRecruitingNCT06602622Phase 4
• DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingNCT06203132Phase 3
• Doravirine Dose Optimisation in PregnancyRecruitingNCT05630638Phase 4
• HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open LabelRecruitingNCT04513626Phase 2
• Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)RecruitingNCT04375800Phase 2
• Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding VolunteersCompletedNCT05648201Phase 4Results posted
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingNCT05631093Phase 3Results posted
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingNCT05630755Phase 3Results posted
• Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant WomenCompletedNCT04900974Phase 1Results posted
• Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)CompletedNCT04689737Phase 4Results posted
• Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedNCT04636437Phase 4Results posted
• Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)CompletedNCT04295772Phase 2Results posted
• Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender WomenCompletedNCT04283656Phase 1Results posted
• Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedNCT04233879Phase 3Results posted
• Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)CompletedNCT04233216Phase 3Results posted
• Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedNCT04223791Phase 3Results posted
• Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected IndividualsCompletedNCT04097925Phase 2Results posted
• Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected IndividualsCompletedNCT04079452Phase 3Results posted
• Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy VolunteersCompletedNCT03894124Phase 1Results posted
• Doravirine, Rifapentine and Isoniazid InteractionCompletedNCT03886701Phase 1Results posted
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and AdolescentsCompletedNCT03332095Phase 1/2Results posted
• Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)CompletedNCT03272347Phase 2Results posted
• Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)CompletedNCT02715700Phase 1Results posted
• Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)CompletedNCT02652260Phase 2Results posted
• A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)CompletedNCT02641067Phase 1Results posted
• Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)CompletedNCT02549040Phase 1Results posted
• Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)CompletedNCT02403674Phase 3Results posted
• Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)CompletedNCT02397096Phase 3Results posted
• A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)CompletedNCT02089659Phase 1Results posted
• A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)CompletedNCT01632345Phase 2Results posted
• A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)CompletedNCT01466985Phase 1Results posted
• A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)CompletedNCT07086079Phase 1
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Active, not recruitingNCT05766501Phase 3
• DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingNCT05705349Phase 3
• Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-ResistanceActive, not recruitingNCT05506605Phase 4
• Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVCompletedNCT04820933Early Phase 1
• ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI ResistanceStatus unknownNCT04429152Phase 3
• HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI ResistanceStatus unknownNCT04334551Phase 4

← Doravirine overview